Presently widely used targets for CAR T cells and bsAbs in preclinical and early clinical stages of development for CRC treatment are epidermal growth factor receptor (EGFR) and carcinoembryonic antigen (CEA) (19, 30, 31). This evidence concerns the gene EGFR and colorectal carcinoma.